top of page
Biosciences
Offspring
Insights & Updates
De-Risking Synucleinopathy Therapeutics: A Human Tissue-First Framework for Target Validation
The transition from preclinical promise to clinical efficacy, the so-called "Translational Gap", remains the most perilous stage of drug development. Nowhere is this chasm wider than in neurodegeneration, where billions of dollars and years of research are lost when promising candidates fail in late-stage trials. The fundamental reason is often a stark divergence between the simplified environments of preclinical models and the complex, heterogeneous reality of human disease.
Featured
Search
Flagship Biosciences and Offspring Biosciences Partner to Provide Complete Global Assay Development Services from Target Identification to Companion Diagnostics
Unlocking the combined value of Offspring’s innovative pre-clinical solutions with Flagship’s clinical trial data-driven assay solutions Broomfield, CO, USA and Södertälje, Sweden – January 24, 2024 Flagship Biosciences, a leader in spatial biology and biomarker analytics services, and Offspring Biosciences, an innovator in pre-clinical biomarker assay solutions, today announced a strategic partnership that aims to further advance precision drug development with a complete bi
Offspring Biosciences
Jan 24, 20242 min read
Anders Nordström. New Chairman of the Board
Join us in welcoming Anders Nordström to the Offspring Biosciences family as the new Chairman of the Board. With a rich background in the Life Science industry, Anders has served and serves as Chairman or Board member for prominent companies such as Pelago Bioscience, Vanadis Diagnostics, Cartana, Halo Genomics, Moleculent, , Genagon Therapeutics, Fenomark Diagnostics and Epigenica. His expertise extends to pivotal roles, including as Senior Advisor for Business Developme
frankhammar
Jan 22, 20241 min read
Offspring Biosciences in research collaboration with BioArctic
We are proud to have the opportunity to work in collaboration together with BioArctic in this study we have been performing IHC binding of Lecanemab in Down syndrome and Alzheimer's disease This study shows for or the first time, Lecanemab (an antibody with higher avidity for toxic Aβ aggregates), binding to Aβ protofibrils and plaques in people with Down syndrome is demonstrated Lecanemab currently in phase 3 clinical studies and has shown to reduce brain amyloid levels in t
-
Sep 16, 20211 min read
bottom of page